Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Yi-hang Zhong"'
Autor:
Yuan-yu Ke, Yu Zhang, Lin Zhongxiao, Songpei Li, Qiudi Deng, Li-juan Huang, Qing Liu, Xue-ping Lei, Xi-Yong Yu, Lu Liang, Min-shan Chen, Jing Chen, Zhan Li, Yi-hang Zhong
Publikováno v:
Acta Pharmacologica Sinica
Non-small cell lung cancer (NSCLC) is characterized by a high incidence of metastasis and poor survival. As epithelial–mesenchymal transition (EMT) is well recognized as a major factor initiating tumor metastasis, developing EMT inhibitor could be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed82a6b1d4d09578d84240d5e8e04e4f
https://doi.org/10.1038/s41401-021-00657-w
https://doi.org/10.1038/s41401-021-00657-w
Autor:
Xue-ping Lei, Yu Zhang, Jijun Fu, Qiudi Deng, Li-juan Huang, Songpei Li, Lingmin Zhang, Yi-hang Zhong, Xi-Yong Yu
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 4, Pp 1-13 (2020)
Cell Death and Disease, Vol 11, Iss 4, Pp 1-13 (2020)
Although angiogenesis inhibitors targeting VEGF/VEGFR2 have been applied for tumor therapy, the outcomes are still unsatisfactory. Thus, it is urgent to develop novel angiogenesis inhibitor for cancer therapy from new perspectives. Identification of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9e4129355b1f3da79c7977a13ff842d
http://europepmc.org/articles/PMC7156472
http://europepmc.org/articles/PMC7156472